NO990723L - Tetrahydrokinolinderivater som EAA antagonister - Google Patents

Tetrahydrokinolinderivater som EAA antagonister

Info

Publication number
NO990723L
NO990723L NO990723A NO990723A NO990723L NO 990723 L NO990723 L NO 990723L NO 990723 A NO990723 A NO 990723A NO 990723 A NO990723 A NO 990723A NO 990723 L NO990723 L NO 990723L
Authority
NO
Norway
Prior art keywords
tetrahydroquinoline derivatives
eaa antagonists
eaa
antagonists
tetrahydroquinoline
Prior art date
Application number
NO990723A
Other languages
English (en)
Other versions
NO990723D0 (no
NO312241B1 (no
Inventor
Romano Di-Fabio
Alessandra Pasquarello
Fabio Maria Sabbatini
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of NO990723D0 publication Critical patent/NO990723D0/no
Publication of NO990723L publication Critical patent/NO990723L/no
Publication of NO312241B1 publication Critical patent/NO312241B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19990723A 1996-08-17 1999-02-16 Tetrahydrokinolinderivater som EAA-antagonister, anvendelse derav, samt fremgangsmåte for fremstilling og farmasöytisksammensetning derav NO312241B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9617305.9A GB9617305D0 (en) 1996-08-17 1996-08-17 Heterocyclic compounds
PCT/EP1997/004440 WO1998007704A1 (en) 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives as eaa antagonists

Publications (3)

Publication Number Publication Date
NO990723D0 NO990723D0 (no) 1999-02-16
NO990723L true NO990723L (no) 1999-04-14
NO312241B1 NO312241B1 (no) 2002-04-15

Family

ID=10798623

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19990723A NO312241B1 (no) 1996-08-17 1999-02-16 Tetrahydrokinolinderivater som EAA-antagonister, anvendelse derav, samt fremgangsmåte for fremstilling og farmasöytisksammensetning derav

Country Status (34)

Country Link
US (1) US6479488B1 (no)
EP (1) EP0922034B1 (no)
JP (1) JP4108129B2 (no)
KR (1) KR100552864B1 (no)
CN (1) CN1131214C (no)
AP (1) AP877A (no)
AR (1) AR008296A1 (no)
AT (1) ATE221052T1 (no)
AU (1) AU724473B2 (no)
BR (1) BR9711311B1 (no)
CA (1) CA2264118C (no)
CO (1) CO4900066A1 (no)
CZ (1) CZ296250B6 (no)
DE (1) DE69714265T2 (no)
DK (1) DK0922034T3 (no)
EA (1) EA001704B1 (no)
ES (1) ES2181030T3 (no)
GB (1) GB9617305D0 (no)
HU (1) HU225797B1 (no)
ID (1) ID18095A (no)
IL (1) IL128141A0 (no)
IS (1) IS4953A (no)
MY (1) MY116952A (no)
NO (1) NO312241B1 (no)
NZ (1) NZ333812A (no)
PE (1) PE107098A1 (no)
PL (1) PL194532B1 (no)
PT (1) PT922034E (no)
SI (1) SI0922034T1 (no)
TR (1) TR199900336T2 (no)
TW (1) TW449582B (no)
WO (1) WO1998007704A1 (no)
YU (1) YU6799A (no)
ZA (1) ZA977326B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
NZ533566A (en) * 2001-12-28 2007-03-30 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists
AU2004206931A1 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
EP1596867A4 (en) * 2003-02-19 2006-03-22 Merck & Co Inc TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR
CA2550735A1 (en) * 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
CN1950346A (zh) * 2004-04-01 2007-04-18 阿卡蒂亚药品公司 N－去甲基氯氮平的晶形
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
JP4754566B2 (ja) 2005-07-22 2011-08-24 持田製薬株式会社 新規なヘテロシクリデンアセトアミド誘導体
JP5399072B2 (ja) 2005-09-12 2014-01-29 アベラ ファーマスーティカルズ インコーポレイテッド ジメチルスルホキシド（ｄｍｓｏ）若しくは関連化合物、又はそれに関連する臭気を除去するシステム
EP2324838A1 (en) * 2005-09-12 2011-05-25 Abela Pharmaceuticals, Inc. Compositions Comprising Dimethyl Sulfoxide (DMSO)
US8435224B2 (en) 2005-09-12 2013-05-07 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
AU2010313253B2 (en) 2009-10-30 2015-02-19 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis
AU2012321345B2 (en) 2011-10-03 2016-03-17 The University Of Utah Research Foundation Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147732T1 (de) * 1989-03-08 1997-02-15 Merck Sharp & Dohme Tetrahydroquinolin-derivate, verwendbar bei neurodegenerativen krankheiten
ATE221520T1 (de) * 1995-09-29 2002-08-15 Glaxo Wellcome Spa Tetrahydrochinoline als nmda antagonisten

Also Published As

Publication number Publication date
KR20000068172A (ko) 2000-11-25
HU225797B1 (en) 2007-09-28
KR100552864B1 (ko) 2006-02-20
PL194532B1 (pl) 2007-06-29
EP0922034A1 (en) 1999-06-16
AP877A (en) 2000-09-27
DK0922034T3 (da) 2002-11-18
BR9711311B1 (pt) 2009-01-13
JP4108129B2 (ja) 2008-06-25
HUP9903108A3 (en) 2004-04-28
NZ333812A (en) 2000-07-28
IL128141A0 (en) 1999-11-30
DE69714265T2 (de) 2003-03-06
WO1998007704A1 (en) 1998-02-26
SI0922034T1 (en) 2003-02-28
IS4953A (is) 1999-01-22
AU4551897A (en) 1998-03-06
AP9901459A0 (en) 1999-03-31
ZA977326B (en) 1999-02-15
PE107098A1 (es) 1999-01-15
CO4900066A1 (es) 2000-03-27
AU724473B2 (en) 2000-09-21
US6479488B1 (en) 2002-11-12
YU6799A (sh) 2000-03-21
EA001704B1 (ru) 2001-06-25
ID18095A (id) 1998-02-26
TR199900336T2 (xx) 1999-04-21
CN1227544A (zh) 1999-09-01
CA2264118A1 (en) 1998-02-26
TW449582B (en) 2001-08-11
CN1131214C (zh) 2003-12-17
EP0922034B1 (en) 2002-07-24
AR008296A1 (es) 1999-12-29
NO990723D0 (no) 1999-02-16
DE69714265D1 (de) 2002-08-29
CA2264118C (en) 2008-06-17
CZ296250B6 (cs) 2006-02-15
MY116952A (en) 2004-04-30
PT922034E (pt) 2002-12-31
NO312241B1 (no) 2002-04-15
BR9711311A (pt) 1999-08-17
JP2001508031A (ja) 2001-06-19
ATE221052T1 (de) 2002-08-15
EA199900121A1 (ru) 1999-10-28
GB9617305D0 (en) 1996-09-25
CZ52999A3 (cs) 1999-07-14
PL331562A1 (en) 1999-07-19
ES2181030T3 (es) 2003-02-16

Similar Documents

Publication Publication Date Title
DK0922034T3 (da) Tetrahydroquinolinderivater som EAA-antagonister
NO20013003D0 (no) Kinolin-derivater
ATE250036T1 (de) Chinolinderivate
DK1073639T3 (da) Chinolinderivater
NO965036L (no) Kinolinderivater som techykinin NK3 reseptor-antagonister
ATE236155T1 (de) Naphthyridin-derivate
ATE240327T1 (de) 1,2-annelierte chinolinderivate
IS1902B (is) Nýjar 19-nor-pregnene afleiður
ATE229005T1 (de) Chinolinderivate
NO991384D0 (no) Substituerte heterocykler som anti-tumormidler
NO974043D0 (no) Indolderivater som EAA-antagonister
ATE255098T1 (de) Substituierte chromanderivate
NO991560D0 (no) PDE IV som inhiberer 2-cyanoiminoimidazol-derivater
ATE255099T1 (de) Substituierte chromanderivate
DK0854867T3 (da) Tetrahydroquinoliner som NMDA-antagonister
DK1086093T3 (da) Tetrahydroquinolinderivater som glycinantagonister
FI954614L (fi) Imidatsolokinoksalinonijohdannaiset EAA-antagonisteina
PT931087E (pt) Novos derivados de piranosido
FI970143A0 (fi) Kinoliinijohdannaiset leukotrieeniantagonisteina
HK1018452A (en) Tetrahydroquinoline derivatives as eaa antagonists
SK2042U (sk) Balkón
ATA73396A (de) 3-methylimino-3-cephemderivate 3-methylimino-3-cephemderivate
ATA69896A (de) 3-methylimino-3-cephemderivate 3-methylimino-3-cephemderivate

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees